Carole Ben-Maimon


Director of Teligent: 2016 - Present

Dr. Ben-Maimon is currently a director, President and Chief Executive Officer of Larimar Therapeutics, Inc. (formerly Zafgen, Inc.) which completed a business combination with Chondrial Therapeutics, Inc. effective May 28, 2020, with Chondrial surviving as a wholly-owned subsidiary of Larimar.  Larimar Therapeutics, Inc. focuses on developing therapies for complex rare diseases, specifically Friedreich's Ataxia.  Prior to the consummation of the merger and from December 2016, Dr. Ben-Maimon served as Chondrial Therapeutics, Inc.’s President, Chief Executive Officer and a member of its Board.  She has over 25 years of experience in the pharmaceutical industry, having held various senior leadership positions at Impax Laboratories, Inc., Qualitest Pharmaceuticals, Inc., Alita Pharmaceuticals, Inc., Barr Pharmaceuticals, Inc., including Duramed Research Inc. (a wholly owned subsidiary of Barr Pharmaceuticals, Inc.), and with Teva Pharmaceuticals USA.  She has also served on the Board of Directors of Barr Pharmaceuticals.  Dr. Ben-Maimon is a graduate of Thomas Jefferson Medical College and received a Bachelor of Arts in biology from The University of Pennsylvania where she graduated magna cum laude. She completed clinical and research training in internal medicine and nephrology at Thomas Jefferson University.

Independent Director